

**Supplementary Table 1.** Baseline characteristics of patients who received atezolizumab+bevacizumab

Variable	Patients (n=115)
Age (years)	60 (31-87)
Sex	
Male	103 (89.6)
Female	12 (10.4)
Etiology	
MASH	61 (53.0)
HBV	33 (28.7)
HCV	12 (10.4)
Others	9 (7.9)
Comorbidities	
Diabetes mellitus	44 (38.2)
Hypertension	40 (34.8)
Cirrhosis	
Yes	98 (85.2)
No	17 (14.8)
CTP	
CTP A	39 (39.8)
CTP B	59 (60.2)
MVI and EHS	
MVI	38 (33.1)
EHS	15 (13.0)
Both MVI and EHS	20 (17.4)
Neither	42 (36.5)
BCLC	
B	14 (14.3)
C	84 (85.7)
AFP >400 (ng/mL)	46 (40.0)
Prior LRT	18 (15.7)
mRECIST	
CR	13 (11.3)
PR	21 (18.3)
SD	16 (13.9)
PD	26 (31.3)
NE	29 (25.2)
Alive	73 (63.5)
Dead	42 (36.5)

Values are presented as median (range) or number (%).

MASH, metabolic dysfunction associated steatohepatitis; HBV, hepatitis B virus; HCV, hepatitis C virus; CTP, Child Turcotte Pugh; MVI, macrovascular invasion; EHS, extrahepatic spread; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; LRT, locoregional therapy; mRECIST, modified response evaluation criteria in solid tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluated.